[{"orgOrder":0,"company":"Medical Life Care Planners, LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tetrahydrocannabivarin","moa":"cannabinol derivatives","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Medical Life Care Planners, LLC","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Strip","sponsorNew":"Medical Life Care Planners, LLC \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Medical Life Care Planners, LLC \/ Undisclosed"},{"orgOrder":0,"company":"InMed Pharmaceuticals","sponsor":"Baymedica","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tetrahydrocannabivarin","moa":"cannabinol derivatives","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"InMed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InMed Pharmaceuticals \/ Baymedica","highestDevelopmentStatusID":"1","companyTruncated":"InMed Pharmaceuticals \/ Baymedica"},{"orgOrder":0,"company":"InMed Pharmaceuticals","sponsor":"Radicle Science","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tetrahydrocannabivarin","moa":"cannabinol derivatives","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"InMed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InMed Pharmaceuticals \/ Radicle Science","highestDevelopmentStatusID":"15","companyTruncated":"InMed Pharmaceuticals \/ Radicle Science"},{"orgOrder":0,"company":"APIRx","sponsor":"Incannex Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Acquisition","leadProduct":"Tetrahydrocannabivarin","moa":"cannabinol derivatives","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"APIRx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"APIRx \/ Incannex Healthcare","highestDevelopmentStatusID":"4","companyTruncated":"APIRx \/ Incannex Healthcare"},{"orgOrder":0,"company":"Canopy Growth Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tetrahydrocannabivarin","moa":"cannabinol derivatives","graph1":"Undisclosed","graph2":"Phase I","graph3":"Canopy Growth Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Canopy Growth Corporation \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Canopy Growth Corporation \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals for Tetrahydrocannabivarin

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Medical Life Care Planners, LLC

                          Country arrow
                          FNCE
                          Not Confirmed

                          Medical Life Care Planners, LLC

                          Country arrow
                          FNCE
                          Not Confirmed

                          Details : Tetrahydrocannabivarin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Metabolic Syndrome.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          October 10, 2022

                          Lead Product(s) : Tetrahydrocannabivarin

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          FNCE
                          Not Confirmed
                          FNCE
                          Not Confirmed

                          Details : delta 9-dominant tetrahydrocannabivarin, d9-THCV is the naturally-occurring variant found in the Cannabis plant, to create unique health and wellness products.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 09, 2022

                          Lead Product(s) : Tetrahydrocannabivarin

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Undisclosed

                          Sponsor : Baymedica

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          FNCE
                          Not Confirmed
                          FNCE
                          Not Confirmed

                          Details : Tetrahydrocannabivarin, also known as THCV, or d9-THCV, is a naturally occurring compound of the Cannabis sativa plant, and is an analog of the better known major cannabinoid, tetrahydrocannabinol (“THC”).

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 05, 2022

                          Lead Product(s) : Tetrahydrocannabivarin

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Approved FDF

                          Sponsor : Radicle Science

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          FNCE
                          Not Confirmed
                          FNCE
                          Not Confirmed

                          Details : A focus of the combined APIRx and Incannex group will be the ongoing development of APIRx's CheWell, CanQuit and CanQuit-O cannabinoid combination MCGs to treat cannabis addiction, nicotine addiction and opioid addiction.

                          Product Name : CheWell

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          March 24, 2022

                          Lead Product(s) : Tetrahydrocannabivarin

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Preclinical

                          Sponsor : Incannex Healthcare

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          05

                          FNCE
                          Not Confirmed
                          FNCE
                          Not Confirmed

                          Details : THCv is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          January 27, 2022

                          Lead Product(s) : Tetrahydrocannabivarin

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank